News

Eli Lilly is suing four telemedicine companies selling compounded versions of its blockbuster obesity drug Zepbound and its ...
Eli Lilly Wednesday filed lawsuits against four telehealth companies alleging they are deceiving consumers by selling ...
Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly’s weight-loss drug Zepbound and its ...
The weekly shot that's transforming weight loss journeys. Discover how Zepbound is reshaping obesity treatment and offering ...
Zepbound (tirzepatide) is a weekly injectable weight-loss medication. It can be purchased online or in person with a valid ...
Key takeaways Eli Lilly has filed lawsuits against four telehealth companies—Mochi Health, Fella Health, Willow Health, and ...
Pharmaceutical giant Eli Lilly alleges the companies are selling illegal off-brand versions of its best-selling diabetes and ...
The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...
Eli Lilly's robust sales for Mounjaro and Zepbound along with its positive outlook for 2025 also work in its favor. Click ...
Eli Lilly alleges Willow falsely claims its products are safe, effective and superior to its FDA-approved tirzepatide medicines, sold under Lilly's brand names: Mounjaro, which treats diabetes, and ...
Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 ...